Pinealon for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

Pinealon for Health & Longevity

Created on 07/01/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

Pinealon is a synthetic three-part peptide from Russian pineal-gland research, promoted to protect nerve cells, sharpen thinking, and slow aging. Its gene-switching idea is striking but unproven. The evidence is mostly cell and animal work plus a few small reports from its own developers. No large human studies exist, and it is sold unregulated. (Full Review)

Protocol

Dose
~1 mg per dose
Subcutaneous injection or intranasal spray; oral capsules exist but with lower expected bioavailability
Course
~10–20 days
Short cycles, sometimes repeated 2–3 times per year rather than continuously; often 5 days per week during a course
Timing
Morning or early afternoon
Once-daily single dosing during a limited course; earlier dosing limits sleep disruption
Time to effect
Sleep & subjective effects
Weeks to a few months
Anecdotal reports over intermittent use
Cellular & animal effects
Rapid
Human onset unquantified
Validated timeline
None exists
No validated time-to-effect timeline has been established

Benefits

Contraindications
  • Pregnancy or breastfeeding
  • Active malignancy or cancer within the past ~5 years
  • Seizure disorder
  • Children and adolescents (<18 years)
  • Prescription CNS medications without physician oversight
    •
Key Interactions
  • Prescription CNS antidepressants, SSRIs/SNRIs (sertraline, venlafaxine)
  • Prescription antiseizure medications (valproate, lamotrigine, levetiracetam)
  • OTC melatonin and sedating antihistamines (diphenhydramine)
  • Other Khavinson-type peptides (Epitalon), melatonin, 5-HTP or L-tryptophan
    •

Risk & Side Effects

  • High: [risks_high]
    •
  • Medium: [risks_medium]
    •
  • Low: Unknown long-term safety and absence of human trials; injection-site and route-related reactions; mild central and gastrointestinal effects
    •
  • Speculative: Pro-oxidant effect and suppression of blood-cell formation; theoretical cancer and uncontrolled-growth risk; sourcing-related contamination and mislabeling
    •

Monitoring

Marker Target Why
Complete blood count (CBC), incl. WBC & platelets WBC 4.0–10.0 ×10ⁿ/L; platelets 150–400 ×10ⁿ/L Screens for the reported suppression of blood-cell formation
hs-CRP (high-sensitivity C-reactive protein) < 1.0 mg/L General marker of inflammation/oxidative burden the peptide is claimed to affect
Fasting glucose & HbA1c Glucose 70–90 mg/dL; HbA1c < 5.4% Metabolic baseline in older users; context for general aging status
Comprehensive metabolic panel (liver & kidney) Within lab-normal, optimal mid-range Confirms no organ stress that would complicate any peptide use

Cadence: Baseline before starting; recheck CBC at end of course / after 4–6 weeks, then every 6–12 months with continued cyclical use

Qualitative Assessment

  • Sleep quality and, if trackable, REM/deep-sleep duration via a validated wearable
  • Daytime energy and alertness
  • Cognitive clarity, memory, and focus
  • Mood and stress resilience
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.